Foghorn Therapeutics Inc. FHTX
Regular-session close
After hours · Nov 19, 4:01 PM ET
- YTD
- -67.04%
- 1 year
- -63.37%
- Market cap
- 106.73M
- Revenue (ttm)
- 25.52M
- EPS (ttm)
- 0.09
- Shares out
- 55.59M
- P/E ratio
- 19.78
- Forward P/E
- -3.12
- YTD return
- -67.04%
- 1-year return
- -63.37%
- 50-day average
- 7.50
- Volume
- 484.01K
- Avg volume
- 850.79K
- Open
- 1.79
- Previous close
- 1.79
- Day's range
- 1.77 – 1.85
- 52-week range
- 1.73 – 7.61
- Beta
- 3.15
- Analysts
- Buy
- Price target
- 12.00 (+574.2%)
Key statistics
- 200-day average
- 6.85
- Enterprise value
- 57.42M
- Price / sales
- 10.74
- Revenue growth
- -55.30%
- Free cash flow
- -42.25M
- Total cash
- 267.40M
- Total debt
- 39.07M
- Short % of float
- 2.11%
Fundamental scorecard
10 of 25 checks passed on FHTX’s reported financials
10of 25 checks passed
- Value 2 of 5
- Growth 3 of 5
- Profitability 2 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2024 | Sep 1, 2024 | -0.42 | -0.31 | +0.11 | +26.19% |
| Aug 8, 2024 | Jun 1, 2024 | -0.60 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.60 | -0.45 | +0.15 | +25.00% |
| May 6, 2024 | Mar 1, 2024 | -0.55 | — | — | — |
| May 6, 2024 | Mar 1, 2024 | -0.55 | -0.59 | -0.04 | -7.27% |
| Mar 7, 2024 | Dec 1, 2023 | -0.79 | -0.57 | +0.22 | +27.85% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 16, 2024 | Jefferies | main | Buy | Buy |
| Sep 24, 2024 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Sep 3, 2024 | Jefferies | init | — | Buy |
| Aug 19, 2024 | Evercore ISI Group | init | — | Outperform |
| Aug 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- foghorntx.com
News
Your note
Sign in to keep a note on FHTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGRESTA SAMUEL M.D. | Officer | Conversion of Exercise of derivative security | Aug 15, 2023 | 0 |
| BELLON STEVEN F | Officer | Sale | Sep 8, 2024 | 101,957 |
| CAVALIE FANNY | Officer | Sale | Mar 10, 2024 | 75,992 |
| COSTA CARLOS FERNANDO | Officer | Conversion of Exercise of derivative security | Sep 22, 2024 | 0 |
| GOTTSCHALK ADRIAN | Chief Executive Officer | Stock Gift | Aug 16, 2023 | 511,704 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Flagship Pioneering Inc. | 22.80% | 12,674,120 | 62.48M | Sep 29, 2024 |
| FMR, LLC | 11.39% | 6,333,984 | 31.23M | Sep 29, 2024 |
| BVF Inc. | 9.54% | 5,302,000 | 26.14M | Sep 29, 2024 |
| Deerfield Management Company, L.P. (Series C) | 5.45% | 3,027,886 | 14.93M | Sep 29, 2024 |
| Raymond James & Associates, Inc. | 4.13% | 2,297,319 | 11.33M | Sep 29, 2024 |
| Blackrock Inc. | 3.26% | 1,811,302 | 8.93M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 3.42% | 1,902,557 | 9.38M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.73% | 962,180 | 4.74M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.11% | 618,263 | 3.05M | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 1.08% | 601,441 | 2.97M | Oct 30, 2024 |
| Fidelity Growth Company K6 Fund | 1.04% | 579,446 | 2.86M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.93% | 519,704 | 2.56M | Sep 29, 2024 |
